Advances in Relapsed/Refractory Multiple Myeloma: Practical Guidance for Newly Approved and Emerging Therapies

Download these slides from a live webinar for the most recent data on the optimal treatment options for patients with relapsed or refractory myeloma, including information on how to incorporate these agents into your current clinical practice.
Sagar Lonial, MD
Kathryn Maples, PharmD, BCOP
Format: Microsoft PowerPoint (.ppt)
File Size: 1.01 MB
Released: May 4, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
Bristol-Myers Squibb
Karyopharm Therapeutics

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

Addition of venetoclax to lenalidomide and rituximab in untreated MCL was well tolerated, showed preliminary anticancer efficacy, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue